Faeth Therapeutics (FTH): Montanova Capital, LLC added to its stake +1.99M shares

2.02M

Shares reported · +1.99M vs prior quarter

0.92%

Disclosed portfolio weight

$50.5M

Reported value

Holdings as of

Jun 30, 2026

Filed

Aug 14, 2026

The story around this disclosure

Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.

1. Jun 10, 2026Company filing · Form 8-K · Agreement ended, Executive changeChanged a top executive or board member, and ended an important agreement (and 3 more items)“Departure of Directors or Certain Officers; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. Chief Executive Officer Appointment The Board of Directors (the “Board”) of the Company appointed Anand Parikh as President and Chief Executive Officer of the Company, effective as of June 13, 2026 (the “Effective Date”).”
2. Jun 15, 2026Company filing · Form 8-K · Material agreement, Other newsSigned an important agreement, and reported other company news
3. Jul 21, 2026Company filing · Form 8-K · Executive changeChanged a top executive or board member“On July 21, 2026, the Board of Directors (the “Board”) of Faeth Therapeutics, Inc. (the “Company”), upon the recommendation of the Compensation Committee of the Board (the “Compensation Committee”), approved one-time supplemental grants of performance-based stock options (“Performance Options”) under the Company’s 2026 Equity Incentive Plan (the “2026 Plan”) to current employees of the Company who were employed with…”
4. Aug 4, 2026Company filing · Form 8-K · ResultsReported its results

What came next

1. Sep 11, 2026Company filing · Form 8-K · Executive changeChanged a top executive or board member“On September 11, 2026, the Board of Directors (the “Board”) of Faeth Therapeutics, Inc. (the “Company”) increased the size of the Board from five to six directors and appointed Karen Vousden, Ph.D. to serve as a Class II director, effective immediately.”
2. Oct 23, 2026Company filing · Form 8-K · Executive changeChanged a top executive or board member“On October 23, 2026, the Board of Directors (the “Board”) of Faeth Therapeutics, Inc. (the “Company”) increased the size of the Board from six to seven directors and appointed Adam Schayowitz to serve as a Class III director, effective immediately.”
3. Nov 3, 2026Company filing · Form 8-K · ResultsReported its results
4. Nov 13, 20265% stakeMontanova Capital, LLC reported a passive stake (13G) of 8.9%

How to read SEC Form 13F-HR

Form 13F is the quarterly report in which investment managers that oversee $100 million or more list the US-listed stocks and some other securities they held on the last day of the quarter.

Full guide: What is an SEC Form 13F?

What else is on file for Faeth Therapeutics

OQRO holds no insider, Congress, fund or contract record for Faeth Therapeutics dated in the last 90 days.

These are records OQRO holds, counted by their date, not a measure of how much trading took place. Routine paperwork such as option exercises and tax withholding is left out. Everything for the company is on its FTH page.

How this filing works

• SEC Form 13F

Other disclosures at Faeth Therapeutics

• SEC Form 13F-HRAug 14, 2026

Everything OQRO holds on this company is on its FTH page.